Leukoencephalopathies Associated with Macrocephaly

 

 Buy Article Permissions and Reprints

Abstract

Macrocephaly, enlarged head size, can be seen in a wide range of conditions including hydrocephalus and genetic syndromes. Benign familial macrocephaly may be seen in multiple generations and is not associated with neurologic concerns. When macrocephaly is seen in conjunction with abnormal white matter on neuroimaging, specific genetic leukoencephalopathies should be considered, including Alexander's disease, Canavan's disease, childhood ataxia with central hypomyelination/ vanishing white matter disease (CACH/VWMD), glutaric aciduria type I, L2-hydroxyglutaric aciduria, and megalencephalic leukoencephalopathy with subcortical cysts (MLC).

• References

• 1 Olney AH. Macrocephaly syndromes. Semin Pediatr Neurol 2007; 14 (3) 128-135
  CrossrefPubMedGoogle Scholar
• 2 Williams CA, Dagli A, Battaglia A. Genetic disorders associated with macrocephaly. Am J Med Genet A 2008; 146A (15) 2023-2037
  Google Scholar
• 3 Sawaishi Y. Review of Alexander disease: beyond the classical concept of leukodystrophy. Brain Dev 2009; 31 (7) 493-498
  CrossrefPubMedGoogle Scholar
• 4 Messing A, Daniels CM, Hagemann TL. Strategies for treatment in Alexander disease. Neurotherapeutics 2010; 7 (4) 507-515
  CrossrefPubMedGoogle Scholar
• 5 Flint D, Brenner M. Alexander disease. In: Raymond G, Eichler F, Fatemi A, Naidu S, , eds. Leukodystrophies. London: Mac Keith Press; 2011: 106-129
  Google Scholar
• 6 Balbi P, Salvini S, Fundarò C , et al. The clinical spectrum of late-onset Alexander disease: a systematic literature review. J Neurol 2010; 257 (12) 1955-1962
  CrossrefPubMedGoogle Scholar
• 7 van der Knaap MS, Naidu S, Breiter SN , et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22 (3) 541-552
  PubMedGoogle Scholar
• 8 van der Voorn JP, Pouwels PJ, Salomons GS, Barkhof F, van der Knaap MS. Unraveling pathology in juvenile Alexander disease: serial quantitative MR imaging and spectroscopy of white matter. Neuroradiology 2009; 51 (10) 669-675
  CrossrefPubMedGoogle Scholar
• 9 Michals K, Matalon R. Canavan disease. In: Raymond G, Eichler F, Fatemi A, Naidu S, , eds. Leukodystrophies. London: Mac Keith Press; 2011: 156-169
  Google Scholar
• 10 Surendran S, Michals-Matalon K, Quast MJ , et al. Canavan disease: a monogenic trait with complex genomic interaction. Mol Genet Metab 2003; 80 (1-2) 74-80
  CrossrefPubMedGoogle Scholar
• 11 Matalon R, Michals-Matalon K. Biochemistry and molecular biology of Canavan disease. Neurochem Res 1999; 24 (4) 507-513
  CrossrefPubMedGoogle Scholar
• 12 Zano S, Malik R, Szucs S, Matalon R, Viola RE. Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease. Mol Genet Metab 2011; 102 (2) 176-180
  CrossrefPubMedGoogle Scholar
• 13 van der Knaap MS, Barth PG, Gabreëls FJ , et al. A new leukoencephalopathy with vanishing white matter. Neurology 1997; 48 (4) 845-855
  CrossrefPubMedGoogle Scholar
• 14 van der Knaap MS, Leegwater PA, Könst AA , et al. Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter. Ann Neurol 2002; 51 (2) 264-270
  CrossrefPubMedGoogle Scholar
• 15 Bugiani M, Boor I, Powers JM, Scheper GC, van der Knaap MS. Leukoencephalopathy with vanishing white matter: a review. J Neuropathol Exp Neurol 2010; 69 (10) 987-996
  CrossrefPubMedGoogle Scholar
• 16 van der Lei HD, van Berkel CG, van Wieringen WN , et al. Genotype-phenotype correlation in vanishing white matter disease. Neurology 2010; 75 (17) 1555-1559
  CrossrefPubMedGoogle Scholar
• 17 Maletkovic J, Schiffmann R, Gorospe JR , et al. Genetic and clinical heterogeneity in eIF2B-related disorder. J Child Neurol 2008; 23 (2) 205-215
  CrossrefPubMedGoogle Scholar
• 18 Scali O, Di Perri C, Federico A. The spectrum of mutations for the diagnosis of vanishing white matter disease. Neurol Sci 2006; 27 (4) 271-277
  CrossrefPubMedGoogle Scholar
• 19 Pineda M, R-Palmero A, Baquero M , et al. Vanishing white matter disease associated with progressive macrocephaly. Neuropediatrics 2008; 39 (1) 29-32
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Labauge P, Horzinski L, Ayrignac X , et al. Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. Brain 2009; 132 (Pt 8) 2161-2169
  CrossrefPubMedGoogle Scholar
• 21 Goodman SI. Development of pathogenic concepts in glutaryl-CoA dehydrogenase deficiency: the challenge. J Inherit Metab Dis 2004; 27 (6) 801-803
  CrossrefPubMedGoogle Scholar
• 22 Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet C Semin Med Genet 2003; 121C (1) 38-52
  CrossrefPubMedGoogle Scholar
• 23 Kölker S, Greenberg CR, Lindner M, Müller E, Naughten ER, Hoffmann GF. Emergency treatment in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27 (6) 893-902
  CrossrefPubMedGoogle Scholar
• 24 Lindner M, Kölker S, Schulze A, Christensen E, Greenberg CR, Hoffmann GF. Neonatal screening for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27 (6) 851-859
  CrossrefPubMedGoogle Scholar
• 25 Heringer J, Boy SP, Ensenauer R , et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol 2010; 68 (5) 743-752
  CrossrefPubMedGoogle Scholar
• 26 Christensen E, Ribes A, Merinero B, Zschocke J. Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27 (6) 861-868
  CrossrefPubMedGoogle Scholar
• 27 Neumaier-Probst E, Harting I, Seitz A, Ding C, Kolker S. Neuroradiological findings in glutaric aciduria type I (glutaryl-CoA dehydrogenase deficiency). J Inherit Metab Dis 2004; 27 (6) 869-876
  CrossrefPubMedGoogle Scholar
• 28 Twomey EL, Naughten ER, Donoghue VB, Ryan S. Neuroimaging findings in glutaric aciduria type 1. Pediatr Radiol 2003; 33 (12) 823-830
  CrossrefPubMedGoogle Scholar
• 29 Bähr O, Mader I, Zschocke J, Dichgans J, Schulz JB. Adult onset glutaric aciduria type I presenting with a leukoencephalopathy. Neurology 2002; 59 (11) 1802-1804
  CrossrefPubMedGoogle Scholar
• 30 Kölker S, Christensen E, Leonard JV , et al. Diagnosis and management of glutaric aciduria type I—revised recommendations. J Inherit Metab Dis 2011; 34 (3) 677-694
  CrossrefPubMedGoogle Scholar
• 31 Mühlhausen C, Hoffmann GF, Strauss KA , et al. Maintenance treatment of glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27 (6) 885-892
  CrossrefPubMedGoogle Scholar
• 32 Rzem R, Van Schaftingen E, Veiga-da-Cunha M. The gene mutated in l-2-hydroxyglutaric aciduria encodes l-2-hydroxyglutarate dehydrogenase. Biochimie 2006; 88 (1) 113-116
  CrossrefPubMedGoogle Scholar
• 33 Rzem R, Vincent MF, Van Schaftingen E, Veiga-da-Cunha M. L-2-hydroxyglutaric aciduria, a defect of metabolite repair. J Inherit Metab Dis 2007; 30 (5) 681-689
  CrossrefPubMedGoogle Scholar
• 34 Barbot C, Fineza I, Diogo L , et al. L-2-Hydroxyglutaric aciduria: clinical, biochemical and magnetic resonance imaging in six Portuguese pediatric patients. Brain Dev 1997; 19 (4) 268-273
  CrossrefPubMedGoogle Scholar
• 35 Moroni I, D'Incerti L, Farina L, Rimoldi M, Uziel G. Clinical, biochemical and neuroradiological findings in L-2-hydroxyglutaric aciduria. Neurol Sci 2000; 21 (2) 103-108
  CrossrefPubMedGoogle Scholar
• 36 D'Incerti L, Farina L, Moroni I, Uziel G, Savoiardo M. L-2-Hydroxyglutaric aciduria: MRI in seven cases. Neuroradiology 1998; 40 (11) 727-733
  CrossrefPubMedGoogle Scholar
• 37 Yilmaz K. Riboflavin treatment in a case with l-2-hydroxyglutaric aciduria. Eur J Paediatr Neurol 2009; 13 (1) 57-60
  CrossrefPubMedGoogle Scholar
• 38 van der Knaap MS, Barth PG, Stroink H , et al. Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. Ann Neurol 1995; 37 (3) 324-334
  CrossrefPubMedGoogle Scholar
• 39 Leegwater PA, Yuan BQ, van der Steen J , et al. Mutations of MLC1 (KIAA0027), encoding a putative membrane protein, cause megalencephalic leukoencephalopathy with subcortical cysts. Am J Hum Genet 2001; 68 (4) 831-838
  CrossrefPubMedGoogle Scholar
• 40 Ilja Boor PK, de Groot K, Mejaski-Bosnjak V , et al. Megalencephalic leukoencephalopathy with subcortical cysts: an update and extended mutation analysis of MLC1. Hum Mutat 2006; 27 (6) 505-512
  CrossrefPubMedGoogle Scholar
• 41 López-Hernández T, Ridder MC, Montolio M , et al. Mutant GlialCAM causes megalencephalic leukoencephalopathy with subcortical cysts, benign familial macrocephaly, and macrocephaly with retardation and autism. Am J Hum Genet 2011; 88 (4) 422-432
  CrossrefPubMedGoogle Scholar
• 42 López-Hernández T, Sirisi S, Capdevila-Nortes X , et al. Molecular mechanisms of MLC1 and GLIALCAM mutations in megalencephalic leukoencephalopathy with subcortical cysts. Hum Mol Genet 2011; 20 (16) 3266-3277
  CrossrefPubMedGoogle Scholar
• 43 Gorospe JR, Singhal BS, Kainu T , et al. Indian Agarwal megalencephalic leukodystrophy with cysts is caused by a common MLC1 mutation. Neurology 2004; 62 (6) 878-882
  CrossrefPubMedGoogle Scholar
• 44 Shukla P, Gupta N, Ghosh M , et al. Molecular genetic studies in Indian patients with megalencephalic leukoencephalopathy. Pediatr Neurol 2011; 44 (6) 450-458
  CrossrefPubMedGoogle Scholar
• 45 van der Knaap MS, Lai V, Köhler W , et al. Megalencephalic leukoencephalopathy with cysts without MLC1 defect. Ann Neurol 2010; 67 (6) 834-837
  PubMedGoogle Scholar